Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2023

Year

Lori M. Laffel, Thomas Danne, Georgeanna J. Klingensmith, William V. Tamborlane, Steven M. Willi, Philip Zeitler, Dietmar Neubacher, Jan Marquard, Margarita Barrientos Perez, Kathleen E. Bethin,

The Lancet Diabetes & Endocrinology

Metabolic SyndromeDiabetes ManagementYoung PeopleCardiovascular DiseaseInsulin ManagementDiabetesPharmacologyClinical TrialsType 2Parallel GroupPharmacotherapyDiabetes MellitusMedicineHealth Sciences